AstraZeneca Results Presentation Deck

Accelerating the expansion into immunology Alexion: immune-mediated rare disease global leader 10 B AstraZeneca Compelling scientific complementarity and synergy Combination of two science- and patient-centric organisations Further-sustained, industry-leading double-digit revenue growth Improved profitability and strengthened cash flow ALEXION B

View entire presentation